Nominally significantly lower rates than in the placebo group were seenwith regard to myocardial infarction in the group that received the 150-mg dose of canakinumab ; with regard to hospitalization for unstable angina that led to urgent revascularization in the 150-mg group and the 300-mg group; and with regard to any coronary revascularization in all three dose groups.